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ABSTRACT
Objective To conduct a systematic review of published 
literature on advanced neuroimaging, fluid biomarkers 
and genetic testing in the assessment of sport-related 
concussion (SRC).
Data sources Computerised searches of Medline, 
PubMed, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), PsycINFO, Scopus and Cochrane 
Library from 1 January 2000 to 31 December 2016 were 
done. There were 3222 articles identified.
Study selection In addition to medical subject heading 
terms, a study was included if (1) published in English, 
(2) represented original research, (3) involved human 
research, (4) pertained to SRC and (5) involved data 
from neuroimaging, fluid biomarkers or genetic testing 
collected within 6 months of injury. Ninety-eight studies 
qualified for review (76 neuroimaging, 16 biomarkers 
and 6 genetic testing).
Data extraction Separate reviews were conducted 
for neuroimaging, biomarkers and genetic testing. A 
standardised data extraction tool was used to document 
study design, population, tests employed and key 
findings. Reviewers used a modified quality assessment 
of studies of diagnostic accuracy studies (QUADAS-2) 
tool to rate the risk of bias, and a modified Grading 
of Recommendations Assessment, Development, and 
Evaluation (GRADE) system to rate the overall level of 
evidence for each search.
Data synthesis Results from the three respective 
reviews are compiled in separate tables and an 
interpretive summary of the findings is provided.
Conclusions Advanced neuroimaging, fluid biomarkers 
and genetic testing are important research tools, but 
require further validation to determine their ultimate 
clinical utility in the evaluation of SRC. Future research 
efforts should address current gaps that limit clinical 
translation. Ultimately, research on neurobiological 
and genetic aspects of SRC is predicted to have major 
translational significance to evidence-based approaches 
to clinical management of SRC, much like applied clinical 
research has had over the past 20 years.
INTRODUCTION
Over the past decade, there has been major prog-
ress in the methods for evaluation of sport-related 
concussion (SRC) and in determining the natural 
history of clinical recovery after injury.1–4 Critical 
questions remain, however, about the acute neuro-
biological effects of SRC on brain structure and 
function, and the eventual time course of physio-
logical recovery after injury.
Studies using advanced neuroimaging techniques 
have demonstrated that concussion is associated 
with metabolic and physiological changes in the 
brain, which correlate with postconcussive symp-
toms and performance on neurocognitive testing 
during the acute postinjury phase.5–12 In parallel, the 
assessment of novel and selective blood biomarkers 
and genetic testing for traumatic brain injury (TBI) 
has rapidly expanded, but with limited application 
to the study of SRC. Extending from the broader 
TBI literature, there is also increasing interest in 
the role of genetics in predicting risk of injury, 
prolonged recovery and long-term neurological 
health problems associated with SRC and repetitive 
head impact exposure in athletes.13
Clinically, there is a need for diagnostic biomarkers 
as a more objective means to assess the presence/
severity of concussion in athletes. Beyond the poten-
tial diagnostic utility, there is also keen interest in the 
development of prognostic biomarkers of recovery 
after SRC. Emerging data suggest that physiological 
abnormalities may persist beyond the typical window 
of clinical recovery after mild traumatic brain injury 
(mTBI), which raises concerns about risks associated 
with repeat injury during the acute recovery phase.14 15 
Most concerning is that a window of cerebral vulnera-
bility may extend beyond the point of clinical recovery, 
when the brain remains physiologically compromised 
and athletes are at heightened risk of repetitive injury. 
Imaging and blood biomarkers that reliably reflect the 
extent of neuronal, axonal and glial damage and/or 
microscopic pathology could conceivably diagnose 
and predict clinical recovery outcome after SRC. 
We conducted a systematic review of the existing 
literature on the utility of advanced imaging, fluid 
biomarkers and genetic testing in the assessment of 
SRC.
METHODS
Systematic review methodology16 was employed 
to address the following core questions for the 5th 
International Consensus Conference on Concus-
sion in Sport:
 ► What advanced or novel tests can assist in the 
assessment of SRC?
 ► What is the role for advanced neuroimaging?
 ► What is the role for cerebral spinal fluid (CSF), 
blood, and urine and saliva biomarkers?
 ► What is the role for genetic or epigenetic testing?
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Three separate systematic literature searches (neuroimaging, 
biomarkers and genetics) were conducted to address each of the 
outlined questions above. The stepwise approach and workflow 
for our systematic searches were registered with an interna-
tional prospective register of systematic reviews17 (see online 
supplementary appendices 1–3). Prior reviews have separately 
evaluated the state of the science on imaging, biomarkers and 
genetics in the broader spectrum of TBI or SRC,18–22 but this is 
the first integrated review of the most up-to-date evidence on 
these novel technologies specific to SRC.
Databases and search terms
Our literature search used PubMed/Medline, Scopus, Cumula-
tive Index to Nursing and Allied Health Literature (CINAHL), 
PsycINFO and Cochrane Library. Given the focus of this system-
atic review on the evolution of emerging technologies, our search 
was limited to the published literature from 1 January 2000 to 
31 December 2016. The decision to include published literature 
dating back to 2000 was based on the relevance of modern tech-
nologies to our specific review question; this approach is further 
supported by the finding that the earliest publication of arti-
cles meeting our inclusion criteria was 2004 for MRI, 2013 for 
biomarkers and 2015 for genetics. The search strategy was devel-
oped in conjunction with an expert medical librarian, who also 
conducted an independent peer review of the strategy. Table 1 
summarises the combination of key words and medical subject 
headings (MeSH) terms used for the three respective searches. 
A common group of search terms for head injury and sport was 
used for all three searches, then combined with the specific terms 
for searches related to neuroimaging, biomarkers and genetics.
Study selection criteria
In addition to meeting the MeSH term criteria, the basic require-
ments for a study to be included in our search were that the 
article (1) was published in English, (2) represented original 
research, (3) involved human research, (4) pertained only to 
SRC (ie, not non-sports TBI), (5) included data from studies 
involving neuroimaging (including electrophysiological testing), 
fluid biomarkers or genetic testing in the assessment of SRC, 
and (6) had at least one data collection point within 6 months of 
injury. Two reviewers collaboratively screened articles for inclu-
sion. Titles and abstracts were reviewed first, and duplicates and 
irrelevant articles were excluded, followed by full-text screen-
ings. A third reviewer was consulted to resolve discrepancies 
about article inclusion.
Data extraction and analysis
Members of the author group extracted relevant data from 
included studies to populate the data extraction tool for each 
search. The author group then conducted reviews relevant to 
each search based on their respective area of subject matter 
expertise (neuroimaging, biomarkers and genetics). For the 
included studies, a standardised data extraction method was 
used (see tables 2-4 for the data extraction tools for the neuro-
imaging, biomarker and genetic searches). Articles are listed in 
chronological order based on publication year to illustrate the 
pattern and evolution of research over time. Two subject matter 
experts from our working group independently examined all 
retrieved citations to determine eligibility for inclusion.
Assessment of risk of bias and level of evidence
As recommended by the Cochrane Collaboration, a modified 
version of the QUADAS-2 was used to assess the risk of bias 
for identified diagnostic accuracy studies23 (see online supple-
mentary appendix 1). Generalisability was assessed based on the 
degree of representativeness across age, gender and sport. Two 
primary reviewers for each study independently assessed the risk 
of bias in identified studies. Using the modified QUADAS-2 tool, 
the overall risk of bias was assessed (low, moderate and high) for 
each included study. Discrepancies were resolved by consensus 
after consulting with an independent third rater.
A rating for the overall level of evidence was assigned for each 
search area (neuroimaging, biomarkers and genetics) based on a 
simple hierarchical ‘level of evidence’ grading system, modified 
Table 1 Medical subject heading terms and key words used for electronic database searches
Head injury and relevant sports.
(Concussion OR concuss* OR brain injuries OR head injuries OR ((head OR brain) AND injur*) OR Post-Concussion 
Syndrome OR postconcussion* OR Mild traumatic brain injury OR MTBI OR acquired brain injury OR blunt head trauma 
OR Craniocerebral Trauma OR ((‘mild traumatic’ OR acquired) AND brain injur*)) AND (athletes OR sports OR sport OR 
sporting OR athleti* OR athlete* OR recreation OR recreat* OR baseball OR bicycling OR boxing OR cycling OR diving 
OR equestrian OR equine OR football OR Head Protective Devices OR helmet* OR hockey OR lacrosse OR martial arts 
OR karate OR judo OR tae kwon do OR aikido OR mountaineering OR racquet sports OR rugby OR skating OR skiing OR 
snow sports OR soccer OR wrestling)
Neuroimaging search Biomarkers search Genetics search
Advanced or novel tests (Neuroimaging OR radiological OR 
neuroradiological OR brain imaging OR 
Positron-Emission Tomography OR ((PET OR 
MRI) AND (scan OR scans)) OR Magnetic 
Resonance Imaging OR ((structural OR 
Functional) AND MRI) OR spectroscopy 
OR Magnetic Resonance Spectroscopy 
OR Diffusion Tensor Imaging OR Arterial 
Spin Labeling OR Electroencephalography 
OR EEG OR Diagnostic Techniques, 
Neurological OR Magnetoencephalography 
OR Fluid-attenuated inversion recovery 
OR Diagnostic imaging OR Quantitative 
EEG OR QEEG OR event-related potentials 
OR ‘event related potential*’ OR ‘evoked 
potential*’ OR ERP OR scanning OR fMRI 
OR ‘resting-state’ OR ‘resting state’)
(Biomarkers OR biomarker OR 
neuroendocrine OR pituitary OR hormone* 
OR cortisol OR hydrocortisone OR gonadal 
steroid hormones OR growth hormone OR 
thyroid OR SIADH OR Inappropriate ADH 
Syndrome OR ((Cerebrospinal OR ‘cerebro 
spinal’) AND fluid*) OR CSF OR Serum OR 
urine OR saliva OR neuronal OR glial OR 
neuroglia OR axonal OR (Marker* AND 
(immunologic OR laboratory OR clinical OR 
biochemical OR immune OR immunologic 
OR biological OR biologic)))
(Epigenetic* OR Epigenomics OR ‘copy 
number’ OR ‘rare variant*’ OR Genetic 
Variation OR ‘genetic diversit*’ OR 
genotype OR genogroup* OR genotype* 
OR genetics OR genetic* OR mitochondria 
OR mitochond* OR Intracellular signaling 
peptides and proteins OR Polymorphism, 
Genetic OR DNA Copy Number Variations 
OR ‘DNA polymorphism’ OR ‘genotype 
environment interaction’ OR Polymorphism, 
Single Nucleotide OR ‘Intracellular 
signaling’ OR genome OR OR genomics 
OR genom* OR allele OR allel* OR 
chromosomes OR chromosom* OR ‘genetic 
testing’)
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from that established by the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) Working 
Group (see table 5).24 In cases of uncertainty, the full article was 
obtained and any disagreement resolved through discussion and 
consultation with a third reviewer. Finally, a qualitative synthesis 
of the overall level of evidence from each of the three searches 
was conducted by the subject matter experts and reported in 
each results section.
RESULTS
The electronic literature database search identified 3222 arti-
cles. After applying additional requirements and eliminating 
duplicate articles, a total of 98 qualified for further review (76 
neuroimaging, 16 biomarkers and 6 genetic testing). Tables 2–4 
provide a summary of key findings from studies in each domain 
(neuroimaging, biomarkers and genetic testing).
Neuroimaging studies
Seventy-six studies using neuroimaging and electrophysiolog-
ical measures revealed significant effects of SRC by each of 
the modalities assessed in this review. These included diffu-
sion tensor imaging (DTI) (n=18), task-based functional MRI 
(fMRI) (n=15), electroencephalogram (EEG)/quantitative-EEG 
(qEEG:n=16), magnetic resonance spectroscopy (MRS) (n=13), 
and resting-state fMRI (n=8), as well as fewer studies that used 
measures of cerebrovascular reactivity (CVR) (n=4), arterial 
spin labelling (n=5), transcranial magnetic stimulation (TMS) 
(n=3), susceptibility weighted imaging (n=2) and functional 
near-infrared spectroscopy (n=1). Although EEG and TMS 
were not explicitly referenced in our assigned review questions, 
the decision was made to include them in the neuroimaging 
section of the review based on published reports using these 
technologies in the study of SRC. The limited number of studies 
for any specific marker, the varying time frames, the lack of 
standardisation and the different analyses employed make the 
determination of consistent patterns difficult.
Nevertheless, some consistent patterns do emerge. With 
MRS there is a reduction of N-acetylaspartate (NAA; relative to 
creatine and/or choline) predominately in white matter,25–32 with 
some evidence of acute reduction with subsequent recovery by 
30 days postinjury.30 32 Others, however, have reported decreased 
NAA levels more chronically.25 33 Fewer studies have observed 
the effects of SRC on other metabolites,27 31 33–35 although null 
results have also been reported.36 37
The majority of DTI work reports a decrease in mean diffu-
sivity and/or an increase in fractional anisotropy in white matter 
within 6 months postinjury,15 38–44 although opposite patterns 
or null results have been reported.10 37 45 46 In addition, most 
observed a reduction in radial diffusivity,38 39 42 43 whereas both 
increases and decreases in axial diffusivity have been described.39 
40 42 43
The results from task-fMRI studies are more variable. The 
majority used a working memory paradigm leading to varying 
and seemingly contradictory findings, with reports of increased47 
48 and decreased activity in task-related networks (eg, dorsolat-
eral prefrontal cortex).11 49–51 Multiple studies, however, have 
reported additional activity outside of the core task regions 
following SRC in a variety of tasks.11 49 50 52–54 Time since injury, 
task variables and symptom presentation are likely modifying 
factors. In addition, although most studies investigated working 
memory, the type and number of stimuli used (ie, low vs high 
working memory ‘load’) varied largely, which may explain 
apparent discordance in hypoactivation versus hyperactivation 
results reported.
Findings from the resting-state fMRI literature also vary, likely 
because methodologies differ. Nevertheless, the default mode 
network (DMN) is the most extensively studied network in the 
SRC literature. Results have varied across studies, however, as 
Table 4 Data extraction tool for studies using genetic testing
Study design Participants
Review of 
evidence
First author, year
Study 
type Modality Sport Age/level (mean ± SD, range)
Gender 
(M/F) n (control description)
Time from injury to 
examination Risk of bias
McDevitt J, 201587 PCS VNTR/GRIN2A Any 19.5±6.0 years M/F 87 C+ Recovery followed 
prospectively; ≤60 days 
postinjury
High
Gill J, 201685 PCS RNA Any Control: 18.5±0.4 years; 
concussed: 19.4±1.5 years
M/F 15 C+, 16 C- BL, within 6 hours and 7 
days postinjury
Moderate
Madura SA, 201690 PCS SLC17A7 Any 20.0±6.3 years M/F 40 C+ Recovery followed 
prospectively; ≤20 days 
postinjury
High
Merchant-Borna K, 
201686
PCS mRNA FB, IH, 
SCR, LX
Control: 18.5±0.4 years; 
concussed: 19.4±1.5 years
M/F 16 C+, 16 C- teammate 
controls (253 C- at BL 
including C+ athletes)
BL, within 6 hours, and 7 
days postinjury
Moderate
Merritt VC, 201689 PCS APOE Any 19.3±1.5 years M/F 45 C+, 43 C- 10.0±14.3 days postinjury Moderate
Merritt VC, 201688 CS APOE Any Positive ε4 allele group 
19.9±1.4 years; negative ε4 
allele group 20±1.6 years
M/F 42 C+ 9.8±14.6 days postinjury 
(range of 0–72 days)
Moderate
Definitions and coding for Table 4: Author indicates last name of first author. Year refers to year of publication.
Study type coded as follows: CS, clinical series; PCS, prospective cohort study.
Modality refers to specific genetic marker(s) studied: VNTR, variable number tandem repeats; GRIN2A, N-methyl-D-aspartate receptor 2A; APOE, Apolipoprotein e; SLC17A7, 
Solute Carrier Family 17 Member 7.
Sports coded as follows: BX, boxing; FB, football; FH, field hockey; IH, ice hockey; LX, LaCrosse; OT, other; RB, rugby; SCR, soccer; WR, wrestling.
Age/Level coded as follows: Col, college; HS, high school; O, other; P, professional; Y, youth.
F/M indicates gender: F, female; M, male; list both if it applies.
Misc: BL, baseline.
Risk of bias: overall risk of bias rated as low, moderate, high or unclear, based on modified QUADAS-2 critical appraisal tool (see online supplementary appendix 2).
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both increases and decreases in connectivity between DMN 
regions have been reported across and within studies.46 55–57 
Altered functional connectivity has also been observed relative 
to executive function, visual and motor networks.55 58–60
Several studies have demonstrated the effects of SRC on EEG/
qEEG at rest or during different task conditions. Importantly, 
multiple studies assessed electrophysiological changes following 
injury relative to a preinjury baseline measure.4 61–64 For example, 
Cao and Slobounov have reported differences in several EEG 
metrics postinjury relative to baseline.61 62 Measures from qEEG 
have also been shown to be altered at 8 days post-SRC relative 
to baseline,4 and have been associated with concussion severity, 
underlining the potential of electrophysiological measurements 
in the assessment of SRC.65
Consistent findings across the other modalities are difficult 
to assess due to the limited number of studies. However, four 
of five studies that investigated cerebral blood flow following 
SRC reported reductions at the acute and subacute phases (days 
to weeks),14 37 66 and even at more chronic time points (~5 
months).25 An additional study reported no differences in resting 
cerebral blood flow,57 although it did report an increase in CVR, 
consistent with others that showed impaired CVR.67–69
The majority of neuroimaging studies, although of high quality 
and informative, had at least a moderate risk of bias based on 
the scoring criteria outlined in the modified QUADAS-2 tool. 
Most common was the lack of generalisability due to the inclu-
sion of limited age ranges, male athletes focus and/or limited 
sample sizes. Additional factors included a lack of appropriate 
control groups, lack of preinjury enrolment and potential for 
measurement bias due to limited information regarding the defi-
nition/diagnosis of mTBI/SRC. Also, publication bias that limits 
reporting null results should be acknowledged, although this 
issue is not unique to the current literature.
Given the above, it is our opinion that the level of evidence 
for the role of these neuroimaging and electrophysiological 
measures in the clinical assessment of SRC is low (see table 5) 
because the most studies reviewed were not designed to specif-
ically assess clinical potential. Rather, they aimed to assess the 
effects of SRC using that marker. Therefore, for the purposes of 
this review, we make a distinction between the level of evidence 
for the utilisation of these markers for clinical assessment of SRC 
and their use to characterise the pathophysiology involved. It is 
our opinion that there is a significant role for neuroimaging and 
electrophysiological measures in characterising the pathophysi-
ology of SRC.
Fluid biomarker studies
Sixteen papers met our inclusion/exclusion criteria relevant to 
diagnosis or prognosis following sport concussion using fluid 
biomarkers (see table 3). Fourteen papers analysed blood (plasma 
or serum) biomarkers, one paper analysed salivary cortisol, and 
one paper analysed CSF. Eleven papers found significant alter-
ations in one or more of the following blood biomarkers that 
could potentially aid in the diagnosis of SRC: α-amino-3-hy-
droxy-5-methyl-4-isoxazolepropionic acid receptor peptide 
(AMPAR),70 S100 calcium binding protein B (s100B),71–74 total 
tau,72 marinobufagenin,75 plasma soluble cellular prion protein,76 
glial fibrillary acidic protein,76 neuron-specific enolase (NSE),77 
calpain-derived αII-spectrin N-terminal fragment (SNTF),78 
tau-C79 and metabolomics profiling.80 In contrast, NSE,72 visi-
nin-like protein-1,74 total tau,41 74 81 tau-A79 and salivary cortisol82 
did not distinguish concussed athletes from non-concussed 
athletes. Several serum biomarkers such as SNTF,78 quinolinic 
acid,83 prolactin84 and tau-A79 showed early evidence in predicting 
outcomes following sport concussion. Finally, decreased levels of 
amyloid-beta-42 and increased neurofilament light in CSF were 
observed in athletes with postconcussion syndrome, although 
these results were largely driven by athletes with postconcussion 
syndrome duration of more than 1 year.81
Overall risk of bias rating for the fluid biomarker papers 
ranged from moderate to high. High risk of bias occurred most 
commonly due to limited external validity and poor generalis-
ability in terms of gender (males only), age (collegiate athletes) 
and sport (most often football or ice hockey). Other factors 
contributing to moderate to high risk included small sample 
sizes, no control subjects and lack of preseason assessment. 
Based on our review of the existing literature, the overall level 
of evidence for use of fluid biomarkers in the clinical assessment 
of SRC is considered low (see table 5). Early but limited evidence 
does indicate, however, that fluid biomarkers may inform our 
scientific understanding of the underlying pathophysiology of 
concussion in humans.
Genetic testing studies
Outcome after SRC is variable and unpredictable, suggesting 
that factors other than injury severity, such as host genotype, are 
important modulators. Emerging literature on genetic predic-
tors of TBI highlights their relevance,13 and suggests four broad 
contexts in which genetic variation could modulate outcome: 
(1) modulation of the impact of a given neurotrauma ‘dose’ in 
terms of injury extent, (2) modulation of repair mechanisms, 
thus impacting trajectory of recovery and ultimate functional 
outcome, (3) modulation of preinjury traits (eg, resilience) or 
cognition (cognitive reserve), and (4) interactions between 
genetic vulnerabilities to neurobehavioural disorders and 
neurotrauma (ie, role of comorbidities).
Our search strategy identified six papers specifically addressing 
genetic factors in SRC. Of these, two (from the same group) 
studied gene expression acutely (within 6 hours) and subacutely 
(within 7 days) after concussion in essentially the same cohort 
of collegiate athletes.85 86 Comparison of preseason baseline and 
postinjury samples in this cohort of college athletes showed 
differential expression of genes driving immune and inflamma-
tory pathways acutely, and hypothalamic–adrenal–pituitary axis 
function subacutely.
The other four papers tested hypotheses related to specific 
candidate genes. McDevitt et al (2015)87 studied the role of 
variable number tandem repeat (VNTR) alleles in the promoter 
region of GRIN2A (a gene coding an NMDA glutamate receptor 
Table 5 Quality of evidence grades
Grade Definition
High High level of confidence in the strength of the existing findings 
demonstrating reliability, validity and clinical utility of the tool(s) for 
use in the assessment of SRC.
Moderate Moderate level of confidence in the strength of the existing findings 
demonstrating reliability, validity and clinical utility of the tool(s) for 
use in the assessment of SRC.
Low Low level of confidence in the strength of the existing findings 
demonstrating reliability, validity and clinical utility of the tool(s) for 
use in the assessment of SRC.
Very low Very Low level of confidence in the strength of the existing findings 
demonstrating reliability, validity and clinical utility of the tool(s) for 
use in the assessment of SRC.
Quality of evidence is a continuum; any discrete categorisation involves some 
degree of arbitrariness. Nevertheless, advantages of simplicity, transparency and 
vividness outweigh these limitations.
SRC, sport-related concussion.
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subunit) in a cohort of 87 concussed athletes. Recovery times over 
60 days were associated with the long variant of the allele. Two 
studies from Merritt and colleagues88 89 found an association of the 
APOEe4 allele with total symptom score, cognitive and physical 
symptoms, and the presence and severity of headache in a cohort 
of concussed collegiate athletes assessed a mean of 10 days after 
injury. Another study in a cohort of 40 concussed collegiate athletes 
examined the rs74174284 polymorphism in the promoter region 
of the SLC17A7 gene, and found that the C allele was associated 
with prolonged recovery times and poorer motor performance.90
Overall, the risk of bias in reviewed studies was moderate to 
high (related to small sample size, inadequate representation 
across age/gender/sport, poorly defined diagnostic methods for 
concussion, referral bias and failure to include non-concussed 
teammates exposed to repetitive head impacts as controls). The 
overall level of evidence for clinical application was determined 
as low (see table 5), prohibiting endorsement of genetic testing 
for clinical evaluation or management of SRC. However, the 
available studies provide ‘proof of concept’ that genetic assess-
ment might identify those at risk for poor outcomes from SRC, 
even before injury. Although genetic assessment cannot yet be 
endorsed as a clinical tool in SRC management, it certainly 
warrants future research.
DISCUSSION
Over the past 20 years, there has been significant progress in our 
understanding of the underlying neurobiology and pathophysi-
ology of mTBI and concussion from both basic animal models 
and human studies. Collectively, the fact that nearly 100 studies 
included in our systematic review have employed advanced tech-
nologies specifically in the study of SRC over the past 15 years is 
a clear indication of how research in this arena has progressed. 
That said, the current state of this work is limited by several 
factors, including the relatively small number of studies inves-
tigating each modality, small sample sizes across studies, varied 
study design, outcome measures and analytic methods, and lack 
of consistency in the timing of postinjury data collection points, 
and risk of bias due to very limited generalisability across studies.
The collective body included in our systematic review was 
considered to have at least moderate risk of bias based on our 
assessment. The risk of bias rating was clearly affected more by 
limited generalisability than by any inherent or created bias in the 
traditional sense associated with investigator conflicts, research 
design, outside influence, etc. Generalisability was limited largely 
by the size and scope of the study sample (eg, restricted to single 
gender or sport) in several studies. This will be an important 
consideration for future research efforts to overcome.
Ultimately, determining the utility of these advanced technol-
ogies likely divides into two parallel discussions: (1) their use as 
research tools to study changes in brain structure and function 
associated with SRC, and (2) their clinical application as diag-
nostic and prognostic markers of injury and recovery to assist 
in the assessment and management of athletes with SRC, over 
and above our current clinical tools. In terms of their current 
readiness for clinical application, our systematic review rated 
the level of evidence as low for advanced neuroimaging, low 
for fluid biomarkers and low for genetic testing (see table 5). 
At the same time, however, our systematic review generally 
supports the utility of advanced neuroimaging, fluid and genetic 
biomarkers in studies aimed at identifying the neurobiological 
effects of concussion and the natural history of neurobiological 
recovery after injury.
Our rating of the neuroimaging evidence is consistent with 
a recently published position statement from the Radiologic 
Society for North America on the use of advanced neuroimaging 
modalities in the assessment of TBI. Advanced neuroimaging is 
sure to play a critical role in the future study of SRC. Similarly, 
the use of fluid biomarkers has advanced our understanding of 
the pathophysiology of SRC, but the validation of these markers 
is in the preliminary stages. Clinically, blood biomarkers require 
hours of analysis and access to a basic science laboratory, which 
is not currently practical for assessing acute SRC in the compet-
itive sports setting. Future studies with larger samples sizes, 
standardised protocols, and more stringent study designs that 
include baseline testing, appropriate controls, blinded analysis 
and real-life outcome measures, are needed before these markers 
are translated from ‘bench to bedside’.
Further research is critical to determine whether the time 
course of neurobiological recovery is ‘coupled’ with clinical 
or subjective recovery (eg, resolutions of signs, symptoms and 
functional impairments), or the extent to which the tail of 
neurobiological recovery extends beyond the observed endpoint 
of clinical recovery. In a research setting, this work is a critical 
next step towards understanding the pathophysiology of concus-
sion in humans. From a clinical perspective, discoveries along 
these lines also have translational significance to determining 
when athletes achieve full recovery and are fit to safely return 
to activity without elevated risk or vulnerability to additional 
injury. Further, the novel technologies may enable researchers to 
better determine the effects of repetitive head impact exposure 
on brain structure and function, even in the absence of frank 
concussion.
It should be acknowledged that genetic testing is not intended 
for use in the diagnosis of concussion, but has importance in 
determining the factors that influence risk of injury and recovery 
after SRC. Data from genetic studies may provide intriguing 
insights about the host response to concussion, although the 
absence of data on how such differential gene expression affects 
outcome limits inferences about whether these changes consti-
tute a contributory disease mechanism or a reparative host 
response. There is a clear need for large-scale research efforts to 
determine the role that genetics plays in the broader space of TBI 
and with specific relevance to athletes with SRC.
Given the complex pathophysiology of concussion, it is 
considered unlikely that a singular diagnostic and prognostic 
biomarker solution will prevail. Rather, an integrated combina-
tion of specific imaging, fluid and genetic biomarkers is predicted 
to have the greatest utility to clinical care. Ultimately, research on 
neurobiological and genetic aspects of SRC is predicted to have 
major translational significance to evidence-based approaches 
to clinical management of athletes with SRC, much like applied 
clinical research has had over the past 20 years.
RECOMMENDATIONS FOR FUTURE RESEARCH DIRECTIONS
We offer the following recommendations in order to further 
accelerate the field’s understanding of the pathophysiology of 
SRC and to determine the potential of these advanced technolo-
gies for the clinical assessment of SRC:
1. Enrolment of larger sample sizes with greater representation 
across sport, age and sex, particularly studies involving youth 
and female athletes.
2. Preinjury enrolment of athletes to allow truly prospective 
recruitment of consecutive injuries. Although often 
impractical for neuroimaging, collecting biomarkers at 
preinjury would represent an ideal study design.
3. Studies driven by a priori hypotheses based on current 
evidence on neuropathophysiology of concussion from 
preclinical models and non-sport head injury. Exploratory 
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(hypothesis-generating) research may also lead to important 
breakthroughs.
4. Careful consideration regarding the control groups used (eg, 
controlling for head impact exposure vs concussive injury) 
in order to advance our understanding of the effects of both 
concussion and repetitive head impact exposure (without 
concussion) on brain structure and function.
5. Adopt standard injury criteria, time frames of assessment 
and multidimensional measures of outcome and recovery, as 
well as metrics and processing strategies within modalities/
metrics to allow comparison across studies (eg, National 
Institute of Neurological Disorders and Stroke TBI Common 
Data Elements, Canadian Pediatric mTBI Common Data 
Elements).
6. Simultaneous assessment of multiple biomarkers to determine 
the additive value of each marker in the clinical assessment 
of SRC.
7. Rather than simply showing associations between 
measurements and diagnosis or outcome, it is important to 
demonstrate additional benefit of novel biomarkers over 
current approaches.
8. Clinical utility is more likely to derive from biomarker 
combinations rather than individual biomarkers; we 
recommend the exploration of biomarker panels, both 
within and across techniques.
Several limitations of our systematic search and review 
warrant consideration. First, we recognise that the scope of our 
assigned systematic review was purposefully broad in order to 
inform the 5th International Consensus Conference on Concus-
sion in Sport, but still rendered a relatively small number of 
qualifying studies, particularly with respect to fluid biomarkers 
and genetics. In addition to the aforementioned methodological 
limitations that impact the quality of evidence from reviewed 
studies, we also acknowledge the potential for publication bias 
(eg, public reporting of positive findings only) affecting our 
results of the systematic review. Further, articles included for 
review were limited to those published in English language, 
raising the prospect that studies published in other languages are 
not represented here.
CONCLUSION
Our results indicate that advanced neuroimaging, fluid 
biomarkers and genetic testing show significant promise as 
research tools in the study of SRC, but require considerable 
further research to determine their ultimate utility in a clinical 
setting. Future research efforts should address current gaps to 
help guide and accelerate clinical translation.
What are the findings?
 ► Over the past two decades, there has been a major expan-
sion of research on the neurobiology of SRC, marked by the 
increase in number of studies that have employed advanced 
neuroimaging and fluid biomarkers to measure the acute 
effects of SRC on brain structure and function.
 ► These technologies show significant promise as research 
tools, but require considerable further research to determine 
their ultimate clinical utility.
 ► Future research efforts should address current gaps that limit 
clinical translation, including greater consistency across the 
most advanced technology platforms, larger and more repre-
sentative study samples (across age, gender, sport, etc), and 
more rigorous analytic methods across studies.
How might it impact on clinical practice in the future?
 ► Ultimately, this line of research on neurobiological and 
genetic aspects of SRC is predicted to have major transla-
tional significance to evidence-based approaches to clinical 
management of athletes with SRC, much like applied clinical 
research has had over the past 20 years.
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